ArticleThe World Allergy Organization journal2022
Efficacy and safety of subcutaneous immunotherapy with a mixture of glutaraldehyde-modified extracts of
Article in The World Allergy Organization journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07427576 (Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid®/Clustek®/Alxoid® for the Treatment of Dermatophagoides/Blomia Tropicalis Allergy in Real-Life Conditions), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid®/Clustek®/Alxoid® for the Treatment of Dermatophagoides/Blomia Tropicalis Allergy in Real-Life Conditions
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Real-World Effectiveness and Safety of Allergen Immunotherapy with a Combination of Glutaraldehyde-Polymerized Allergen Extracts ofInternational journal of molecular sciences · 2026Article
- Real-World Effectiveness of Polymerized House-Dust-Mite Subcutaneous Immunotherapy up to 24 Months: Why Baseline Symptom Severity Shapes Measurement of the Combined Symptom-Medication Response.Journal of clinical medicine · 2026Article
- Review
- Safety and Effectiveness of Subcutaneous Immunotherapy with a Glutaraldehyde-Polymerized Mite Allergen Extract in Adults and Children with Allergic Rhinitis with or Without Asthma Due toDiseases (Basel, Switzerland) · 2026Article
- Exploring the indicative role of ACT score in improving lung function in asthmatic children undergoing dust mite immunotherapy.BMC pediatrics · 2025Article
- Clinical outcomes of allergen immunotherapy in children in Latin America: Treatment with polymerized allergen extracts ofThe World Allergy Organization journal · 2025Article
- Efficacy and safety of sublingual immunotherapy using a combination ofThe World Allergy Organization journal · 2025Article
- Development of a Ferritin-Based Nano-Allergen and Its Immunological Effects in vitro and in vivo.International journal of nanomedicine · 2025Article
- Selection of allergen extract for immunotherapy in polysensitized allergic rhinitis patients.Immunotherapy · 2024Article
- Frequent IgE recognition ofFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergen Immunotherapy (AIT) is an effective treatment of allergic respiratory diseases induced by the inhalation of house dust mite allergens. Objectives: To evaluate the efficacy and safety of glutaraldehyde polymerized allergen extracts using a mixture of Methods: Two hundred and fifty (250) patients with allergic rhinoconjunctivitis with, or without asthma and sensitized to Results: Significant improvement was found after 3 months of treatment regarding CSMS (p < 0.0001) and ACT (p < 0.0001). Additionally, a significant decrease in medication consumption was found after 3 months of treatment (p < 0.0001). Adverse reactions, either local or systemic were mild and no severe reactions related to the vaccines were observed. Conclusion: After 12 months of allergen immunotherapy, glutaraldehyde-modified mixture of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.